ABSTRACT: Tumor resistance to chemotherapy is the major obstacle to employ cisplatin, one of the broadly used chemotherapeutic drugs, for effective treatment of various tumors in the clinic. Most acknowledged mechanisms of cancer resistance to cisplatin focus on increased nuclear DNA repair or detoxicity of cisplatin. We previously demonstrated that there was a unique metabolic profile in cisplatinresistant (CP-r) human epidermoid adenocarcinoma KB-CP 20 and hepatoma BEL 7404-CP 20 cancer cells. In this study, we further defined hyperpolarized mitochondrial membrane potentials (Δψ m ) in CP-r KB-CP 20 and BEL 7404-CP 20 cells compared to the cisplatin-sensitive (CP-s) KB-3-1 and BEL 7404 cells. Based on the mitochondrial dysfunction, mitaplatin was designed with two mitochondrial-targeting moieties [dichloroacetate (DCA) units] to the axial positions of a six-coordinate Pt(IV) center to sensitize cisplatin resistance. It was found that mitaplatin induced more apoptosis in CP-r KB-CP 20 and BEL 7404-CP 20 cells than that of cisplatin, DCA and cisplatin/DCA compared on an equal molar basis. There was more platinum accumulation in mitaplatin-treated CP-r cells due to enhanced transmembrane permeability of lipophilicity, and mitaplatin also showed special targeting to mitochondria. Moreover, in the case of treatment with mitaplatin, the dramatic collapse of Δψ m was shown in a dose-dependent manner, which was confirmed by FACS and confocal microscopic measurements. Reduced glucose utilization of CP-r cells was detected with specifically inhibited phosphorylation of pyruvate dehydrogenase (PDH) at Ser-232, Ser-293, and Ser-300 of the E1α subunit when treated with mitaplatin, which was indicated to modulate the abnormal glycolysis of resistant cells. The present study suggested novel mitochondrial mechanism of mitaplatin circumventing cisplatin resistance toward CP-r cells as a carrier across membrane to produce CP-like cytotoxicity and DCA-like mitochondria-dependent apoptosis. Therefore, mitochondria targeting compounds would be more vulnerable and selective to overcome cisplatin resistance due to the unique metabolic properties of CP-r cancer cells.
■ INTRODUCTION
cis-Diamminodichloroplatinum II (cisplatin, CP) was the first platinum-based chemotherapeutic drug for clinical treatment of tumors, introduced more than 40 years ago. 1 The chemotherapeutic action of cisplatin is to cross-link with DNA, thereby interfering with transcription and/or DNA replication in tumor cells. 2, 3 Today, cisplatin is widely used to treat cancers, particularly malignant solid tumors such as testicular cancer, ovarian cancer, esophageal cancer, bladder cancer, head and neck cancer, and small-cell lung carcinomas. 4, 5 However, the development of tumor resistance to chemotherapy leads to the failure of cisplatin treatment and forced higher usage of antitumor agents, which also causes formidable side effects experienced by patients. 6 There are certain known mechanisms, including reduced drug uptake, enhanced drug inactivation, increased DNA adduct repair, perturbed cell cycle, and the inhibition of apoptosis, of tumor resistance to cisplatin. 7 All of these processes have the common effect of limited platinum intracellular accumulation and nuclear DNA damage in cisplatin-resistant tumors. Thus, it is critical to identify novel targets and design potential drugs to overcome tumor resistance to cisplatin. Mitochondria are recognized as the power plant of cells, providing energy for various cellular activities. 8 Mitochondrial disorders are related to many kinds of diseases, such as Alzheimer's disease, 9, 10 Parkinson's disease, 11 myopathy, 12 osteoarthritis, 13 cardiovascular hypoxia, 14 and chronic kidney disease. 15 However, the importance of mitochondria as targets for cancer chemotherapy has not been adequately explored or clinically exploited. Many years ago, Dr. Otto Warburg suggested that tumor was due to the altered metabolism of cancer cells, converting glucose oxidation to glycolysis, even under aerobic conditions. 16 The excessive glycolysis and lower O 2 consumption result in the "paradox" of glycolysis under aerobic conditions, and this phenomenon is an adaptation to intermittent hypoxia in premalignant lesions, which contribute to decreased apoptosis of cancer cells. 17 Recent studies have indicated that this glycolytic shift makes the mitochondrial membrane less susceptible to permeabilization. 18 The resulting ''inactivity'' of the mitochondria reduces the likelihood of mitochondrially mediated cell death. 19 Targeting mitochondria might therefore be an effective way to overcome tumor resistance to chemotherapy. 20 Dichloroacetate (DCA) is broadly employed to decrease lactate levels by inhibiting pyruvate dehydrogenase kinase (PDK). 21 With good bioavailability, this small molecule drug has been used in humans with inherited diseases involving mitochondrial metabolism for more than 40 years. Recently, DCA has been found to have new action as anticancer agents. It might enhance apoptosis, as it increases the movement of pyruvate into mitochondria, shifts metabolism from glycolysis to glucose oxidation, increases apoptosis, and decreases cellular proliferation by PDK inhibition. 22 Thus, DCA causes cancer regression by sensitizing cells to chemotherapy via the mitochondrial apoptotic pathway, with minimal effects on normal cells.
Mitaplatin (cis,cis-diamminedichlorobis(dichloroacetate)-platinum(IV)) is a six-coordinate platinum(IV) complex synthesized from cisplatin containing two DCA molecules in the axial positions. Upon reduction, cisplatin and two DCA molecules are released. Previous studies have shown that mitaplatin is able to induce apoptosis without affecting noncancerous cells. 23 In addition, compared to healthy cells, cancer cells are known to have hyperpolarized mitochondrial membrane potentials (Δψ m ). 24 In this study, we focused on the mitochondrial-based difference between cisplatin sensitive and resistant cells. It was found that mitaplatin increased sensitivity of tumor resistant cells by inducing mitochondrial dysfunction. Due to its enhanced lipophilicity, more cytotoxic platinum accumulation in CP-r cells treated with mitaplatin occurred after cisplatin treatment. In addition to inhibiting tumor growth by forming DNA adducts, mitaplatin triggers mitochondrial damage in CP-r cells. There is thus a potential synergistic effect of cisplatin administered with DCA. These properties of mitaplatin provide opportunities for further development of new platinum-based agents with the capability of killing CP-r cells.
■ MATERIALS AND METHODS
Reagents and Materials. Mitaplatin was synthesized, characterized, and kindly gifted by Prof. Stephen J. Lippard's group at the Massachusetts Institute of Technology. Cisplatin and DCA were purchased from Sigma-Aldrich Company (St. Louis, MO). Mitaplatin, cisplatin, and DCA were all dissolved in PBS and further diluted in cell culture medium.
Cell Culture. The human epidermoid adenocarcinoma cell line KB-3-1 and hepatoma cell line BEL 7404 were the parental CP-s cells used in this study. Both of them were originally obtained and authenticated by ATCC, a biological resource center in Manassas, Virginia, and their morphology and propagation assays were performed under standard culture conditions. DNA profiles were analyzed with short tandem repeat (STR) techniques. KB-CP 20 cells were selected from KB-3-1 cells by independent exposure to cisplatin with stepwise increased concentrations up to 20 μg/mL, as were BEL 7404-CP 20 cells. 25 BEL 7404-CP 20 and KB-CP 20 cells were cloned and kindly gifted by Michael M. Gottesman's laboratory at NCI, NIH. Both of them were maintained in medium containing 5 μg/mL cisplatin. The cell lines were all grown as monolayer cultures in atmosphere with 5% CO 2 at 37°C using DMEM (Hyclone, Logan, UT) with 10% fetal bovine serum (ExCell, New Zealand), L-glutamine, penicillin (50 units/mol), and streptomycin (50 μg/mL; Hyclone, Logan, UT). MTT Assay. To examine the cellular cytoxicity of compounds to different cell lines, 5 × 10 3 cells were seeded and cultured for 24 h in 96-well plates and incubated with different concentrations of mitaplatin, cisplatin, cisplatin/DCA, and DCA for 72 h. Cells were stained with 100 μL of sterilized MTT dye ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 0.5 mg/mL, Sigma-Aldrich) for 4 h at 37°C, and 100 μL of DMSO was added. The spectrometric absorbance at 570 nm was measured on a microplate reader (M200, Tecan, Mannedorf, Switzerland).
Apoptosis Measurement. Apoptotic cells were evaluated by morphologic observation and flow cytometry analysis as well as DNA fragmentation assays with confocal microscopy. For morphologic evaluation, cells were seeded in 6-well plates and incubated for 24 h under standard conditions. The medium was replaced with fresh medium containing 100 μM mitaplatin, cisplatin, cisplatin/DCA or 200 μM DCA. After 72 h of incubation, cells were observed directly in a bright field or indirectly in fluorescence after being stained with Hoechst 33342 and propidium iodide (PI), as recommended by the manufacturer (Mbchemic, Shanghai, China), for 30 min and washed three times with PBS (MBI3000B, Leica, Stockach, Germany).
To assay apoptosis, cells were treated with mitaplatin, cisplatin, cisplatin/DCA, or DCA alone ([Pt] or [2DCA] was 50, 100, and 150 μM) for 72 h. A positive control was introduced using the Apoptosis Inducers Kit (Beyotime, Shanghai, China). The samples were harvested by centrifugation and washed with PBS. Each sample was stained with 5 μL of Alexa Fluor 488 annexin V and 2 μL of PI according to the protocol of Alexa Fluor 488 annexin V and PI Cell Apoptosis Kit (Invitrogen, Rockville, MD) for 15 min at room temperature. After staining, 400 μL of binding buffer was added to each tube and analyzed within an hour by flow cytometer (Beckman Coulter Quanta SC, Florence, AL).
Transmission Electron Microscopy (TEM) Imaging. For examination of ultrastructure changes of mitochondria, KB-CP 20 and BEL 7404-CP 20 cells were collected for sample preparation after being treated with mitaplatin or cisplatin for 72 h. Briefly, after harvesting with trypsin and washing twice with 0.1 M PBS (pH 7.4), primary fixation was done with 3% glutaraldehyde in the dark for 24 h at 4°C. The cells were then postfixed in 1% osmium tetroxide (OsO 4 ) for 1 h, dehydrated in a graded ethanol series (50%, 70%, 80%, 90% and 100%), and embedded in a 1:1 mixture of propylene oxide and epoxy resin. Ultrathin sections were cut with diamond knives at 80 nm section thickness using Leica Ultracut UCT microtome (Leica EM UC6, Stockach, Germany). The sections were placed on 300 mesh copper grids and poststained with uranyl acetate and lead citrate. Finally, the sections on grids were observed in an electron microscope (JEOL JEM-1400, Gifu, Japan) at 80 kV. ELISA Measurement. The activity of pyruvate dehydrogenase (PDH) was examined by the PhosphoPDH In-cell ELISA Kit (MitoScience, Eugene, OR). This is a high-throughput assay for measuring up-or downregulation of PDH subunit E1α, as well as phosphorylation at all three E1α regulatory serines: Ser 232, Ser 293, and Ser 300. The kits use quantitative immunocytochemistry to measure protein levels or posttranslational modifications in cultured cells. Cells were seeded in a 96-well flat bottom cell culture plate, and incubated with drugs for 72 h. Then cells were fixed with 4% paraformaldehyde for 20 min. After washing with PBS three times, 100 μL of permeabilization buffer was added to the wells and incubated for 30 min. The nonspecific sites were blocked with 200 μL of blocking buffer and incubated for 2 h. Highly specific monoclonal antibodies for E1α and all three E1α regulatory serines a Data were the mean ± SD from three independent experiments. ***P < 0.001 versus cisplatin treatment group.
(Ser 232, Ser 293, and Ser 300) were added and incubated overnight at 4°C. After the plate was washed, AP/HRP labeled secondary antibody was added and incubated for 1 h. The color was developed in proportion to the amount of E1α and all three phosphorylated E1α regulatory serines. Isolation of Organelles in CP-r Cells and Qualitative Analysis of Pt Concentration. The CP-r KB-CP 20 and BEL 7404-CP 20 cells were grown at a density of 2 × 10 7 cells in 150 mm dishes. After adhesion, cells were exposed to 100 μM mitaplatin or cisplatin for 72 h. Afterward, the cells were trypsinized, washed with PBS three times, and centrifuged for 5 min at 600g. Cell nuclei and mitochondria were isolated by a Nuclear Extraction Kit (Solarbio, Shanghai, China) and a Mitochondria Isolation Kit (Pierce, Rockford, IL) for Cultured Cells, respectively. The whole cells or the isolated organelles were lysed and the protein content was quantified by a BCA Protein Assay Kit (Pierce, Rockford, IL). After digestion, the samples were examined by an inductively coupled plasma mass spectroscopy (ICP-MS, Thermo Biosystems, Rockford, IL)). Standards and blanks were prepared in the same way as the samples.
Statistical Analysis. All experiments were performed at least three times and expressed as means ± SD. Data were analyzed for statistical significance using Student's t test. P < 0.05 was considered statistically significant. The platinum accumulation in isolated mitochondria was examined by ICP-MS. The mitochondrial platinum amounts were increased ∼3-fold after treatment with mitaplatin compared to that of cisplatin (***P < 0.001). (C) The platinum accumulation in isolated cell nuclei was also determined by ICP-MS. Mitaplatin showed its novel dual targets to both nuclei and mitochondria. Data represent the means ± SD of three separate experiments. To confirm the activity of mitaplatin on cell viability, CP-r KB-CP 20 ( Figure 2C ) and BEL 7404-CP 20 ( Figure S1 in the Figure 2C and Figure S1 in the Supporting Information.
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Mitaplatin Increased Intracellular Platinum Accumulation in CP-r Cells. It is generally accepted that tumors become resistant to cisplatin partly because of reduced accumulation of cisplatin in the cytoplasm. 26, 27 It is possible to sensitize CP-r cells by increasing intracellular platinum accumulation. Recent studies demonstrated platinum(IV) complexes were formed to enhance its lipophilicity and to circumvent cisplatin resistance, since its advanced diffusion facilitated the complexes to cross cell membranes. Additionally, increased kinetic inertness makes the complex more stable and provides the opportunity to reach the intracellular target intact. 28−30 To detect the increased mitaplatin accumulation in CP-r cells, intracellular platinum levels were determined by inductively coupled plasma mass spectroscopy (ICP-MS) in the negative ion mode. There was markedly increased platinum (∼3-fold) in CP-r whole cell lysates treated with mitaplatin compared to those treated with cisplatin ( Figure 3A ). This result suggests that apoptosis is more effectively induced and tumor resistance is more efficiently reversed in CP-r cells due to increased drug accumulation.
Mitaplatin Altered Intracellular Platinum Distribution. To further explore the mechanism of mitaplatin, mitochondria, and nuclei in KB-CP 20 and BEL 7404-CP 20 were isolated, respectively. It is well-known that cisplatin is a traditional anticancer agent which targets nuclear DNA. Therefore, consistent with the increased platinum accumulation measured in whole cell lysates ( Figure 3A) , treatment with mitaplatin resulted in the increasing of platinum accumulation in the nuclei as expect ( Figure 3C ). However, compared to cisplatin, mitaplatin simultaneously exhibited its talent to interact with mitochondria, since there was also increased platinum accumulation in the mitochondria of CP-r cells treated with mitaplatin compared to those treated with cisplatin ( Figure 3B ). Mitochondrial localization of platinum might be partially due to DCA ligands in mitaplatin compounds, and these results exhibited the ability of mitaplatin for targeting mitochondria. The dual targets (nuclei and mitochondria) may make mitaplatin more distinguishing and unique to sensitize chemotherapy than other antitumor drugs with a single target. To investigate whether the new target contributed to circumvent cisplatin resistance, the effects of mitochondrial dysfunction were further measured.
Mitaplatin Triggered Mitochondrial Dysfunction in CP-r Cells. Transmission electron microscopy (TEM) was performed to examine mitochondrial ultrastructures of cells treated with different drugs. The cells as control group without treatment had well-defined integral mitochondrial membranes with regular-appearing cristae. After mitaplatin treatment for 72 h, the mitochondria of KB-CP 20 cells showed irregular ultrastructures with more highly condensed shapes compared to mitochondria with cisplatin treatment ( Figure 4A ).
Mitochondrial membrane depolarization was a prelude to apoptosis, and mitochondrial membrane potentials (MMPs) reflected electron transport chain (ETC) activity and mitochondrial function. To explore the unique bioproperties of mitaplatin, activities of mitochondria were measured by quantitative MMPs with JC-1 staining. Mitochondrial depolarization occurring in apoptosis was revealed by a decrease in the red/green fluorescence intensity ratio. Carbonyl cyanide 3-chlorophenyl hydrazone (CCCP), an uncoupled agent that depolarizes mitochondrial membranes, was used as a positive control.
In KB-CP 20 cells, mitaplatin treatment enhanced MMP depolarization when mitaplatin concentration was increased from 50 to 150 μM ( Figure S2 in the Supporting Information). Similar results were obtained with BEL 7404-CP 20 cells ( Figure 4B and Figure S2 in the Supporting Information). The flow cytometry analysis was consistent with the confocal microscopic measurements allowing direct visualization of mitochondria. The ratio of red to green fluorescence intensity was changed with mitaplatin treatment ( Figure 4C ). Morphological abnormality and MMP depolarization of mitochondria suggested that mitaplatin induced apoptosis through triggering dysfunction of mitochondria in CP-r cells. In conclusion, a combination of cisplatin with mitochondrial targeting moieties (DCA) would be an attractive therapeutic strategy for effectively attacking CP-r cancer cells.
Mitaplatin Reduced Glucose Utilization in CP-r Cells. It was demonstrated previously that there was decreased Glucose oxidation is far more efficient in generating ATP (∼36 mol of ATP/mol of glucose) compared with anaerobic glycolysis (∼2 mol of ATP/mol of glucose) or aerobic glycolysis (∼4 mol of ATP/mol of glucose). 33, 34 We further determined whether mitaplatin altered the metabolic balance between the ratio of oxidative phosphorylation and aerobic glycolysis.
Mitaplatin Decreased the Phosphorylation of Pyruvate Dehydrogenase. Pyruvate dehydrogenase (PDH) is a 9.5 megadalton multienzyme complex localized in the mitochondrial matrix. It has three catalytic components, [pyruvate dehydrogenase (E1), dihydrolipoamide acyltransferase (E2), dihydrolipoyl dehydrogenase (E3)], one binding component (E2/E3 binding protein), and two regulatory components [PDK (PDH kinase) and PDP (PDH phosphatase)]. 35, 36 The pyruvate dehydrogenase complex plays a central role in cellular metabolism.
In PDH, the catalytic unit E1 is a heterotetramer of two α and two β subunits. In humans, PDH activity is inhibited by site-specific phosphorylation at three sites on the E1α subunit (Ser 232, Ser 293, and Ser 300). Therefore, the phosphoPDH E1α, as well as the phosphorylation at each individual E1α regulatory serine site, was examined by ELISA ( Figure 6 ). Superior to cisplatin, the phosphorylation of all three regulatory serine sites of E1α was reduced with mitaplatin treatment. Mitaplatin was able to effectively inhibit the PDK activity and reduce phosphorylation at Ser 232, 293, and 300, three regulatory serine residues of E1α.
■ DISCUSSION
Cisplatin is a drug commonly used to treat many cancers at early clinical stages. However, acquired resistance due to largely unknown mechanisms limits its efficacy. This study demonstrates that the mitochondrial membrane potentials in cisplatin resistant cancer cells are more strongly polarized than in sensitive cells. Recently, the critical role of mitochondria in regulating cell growth metabolism has been investigated to distinguish cancerous cells from nonmalignant cells, 22 even to distinguish cancer stem cells from noncancer stem cells. 18, 37 There are amounts of mitochondrial and metabolism-related properties to be identified, such as masses of mitochondria and mitochondrial DNA, MMPs, oxygen/glucose consumption, ROS and ATP, etc. These distinguishing mitochondrial characteristics aid in understanding and mastering the differences between sensitive and resistant cancer cells. An increasing number of studies have suggested that the function and integrity of mitochondria may impact the viability, proliferation/ division, cytotoxic resistance, and hypoxic tolerance. Therefore, the unique properties of mitochondria in this study might become the foundation of designing chemotherapeutic targets for effective cancer treatment. Several mitochondrial targets have been recognized as attractive strategies for overcoming chemotherapeutic resistance. Targets include, for example, (i) mitochondrial permeability transition; (ii) outer membrane permeabilization; (iii) mitochondrial metabolism and metabolic reprogramming. 20, 38 Concerning the mitochondrial characteristics in cancer cells, drugs were designed to activate cell metabolism machinery as a more effective chemotherapeutic administration. To support this standpoint, mitaplatin was employed to circumvent cancer resistance to cisplatin due to its ability to target the hyperpolarized mitochondria.
This study highlighted mitaplatin as a dual target molecule that is able to overcome cisplatin chemoresistance in tumor cells. As expected, mitaplatin exhibited the ability to overcome cisplatin resistance in cancer cells. It was hypothesized that mitaplatin induced apoptosis of resistant cells via the pharmacological mechanisms of triggering MMP depolarization ( Figure 4B and Figure 4C ). Mitaplatin could accumulate inside cells, and the ratio of platinum in mitochondria is 2. Figure 3C ). The advanced mitaplatin intracellular accumulation mainly brought a higher platinum dose in mitochondria and damaged mitochondria, which thereby sensitized the resistant cells and activated a downstream mitochondria-dependent cell death.
Furthermore, once the supplying organelles were dysfunctional, the energy metabolism would be changed for sustaining the metabolic needs of tumor cells. As a metabolic modulator, mitaplatin helps to reduce the energy consumption ( Figure 5 ) and transform the metabolic form by downregulated phosphorylation of PDH (Figure 6 ), leading to shift glycolysis back to oxidative phosphorylation by enchancing the influx of acetyl-CoA into the mitochondria (Figure 7 ). In conclusion, mitaplatin could be an attractive approach for selective targeting of CP-r cancer cells with mitochondria-based agents.
In addition, DCA has been approved as to its effectiveness and safety by the FDA, and synthesis of DCA (as mitochondrial moiety) with cisplatin (as traditional antitumor drug) should be a potential strategy for chemotherapeutic drug development. Most recent studies show that treatment with DCA alone can cause the inhibition of PDK or cause tumor regression with relatively high doses (∼mM). 39−41 However, the high dose inevitably brought extensive adverse reaction to normal tissue, such as neurotoxicity and liver damage, 42, 43 which may limit its usage and increase health risk. In our study, a synergistic effect of cisplatin with DCA (less than 300 μM, Figure 2A ) may be a feasible approach to alleviate this obstacle. Under concentrations used in study, DCA manifested its effect on decreasing the phosPDH E1α level, and there is not cytotoxicity shown in CP-r cells. In conclusion, for future platinum-based drug design, anticancer agents that directly target mitochondria to make CPr cells more susceptible and/or to bypass resistance mechanisms should be further explored. 
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